A method designed to genetically alter laboratory mice can also be used to produce personalised animal models of an aggressive type of malignant brain cancer in children.
List view / Grid view
Filter the results
A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in order to recognise the ideal candidate.
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
A chaperone protein has been identified as a possible therapeutic target for the treatment of Kennedy's disease and prostate cancer.
The ISCT is objecting linking the benefits of cellular immunotherapy with third party offerings of T-cell banking for future therapeutics.
A new drug called IP1867B, which could be used for future treatments of brain tumours, is being examined.
The first genetically modified mini human livers have been grown in a laboratory, to emulate liver disease progression and test therapeutics.
Salk scientists discover a pair of enzymes that drive non-small-cell lung cancer by promoting inflammation which could inform the development of new therapies.
Researchers have used machine learning to discover that the two most widespread DNA structures cause genome mutations that lead to cancer.
Scientists have discovered a way to improve immune-based treatments by modulating T cells.
Researchers haved mapped the crystal structure of a protein to find out how a drug latches onto it.
Osteoarthritis (OA) is a painful and debilitating disease of articular joints.1,2 Its clinical prevalence is as high as 21.6 percent of the population in the United States,3 which constitutes direct health costs of over 80 billion US dollars annually.4